Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma

被引：0
|
作者：
Heather Jacene
John Crandall
Yvette L. Kasamon
Richard F. Ambinder
Steven Piantadosi
Donna Serena
Wayne Kasecamp
Richard L. Wahl
机构：
[1] Johns Hopkins University,Division of Nuclear Medicine, Department of Radiology
[2] Dana-Farber Cancer Institute,Department of Imaging
[3] Johns Hopkins University,Department of Oncology
[4] Cedars-Sinai,Samuel Oschin Comprehensive Cancer Institute
[5] Washington University School of Medicine,Mallinkrodt Institute of Radiology
来源：
Molecular Imaging and Biology | 2017年 / 19卷
关键词：
[; I]tositumomab; Hodgkin lymphoma; Hodgkin; FDG; Bexxar;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：429 / 436
页数：7
相关论文
共 50 条
  • [1] Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma
    Jacene, Heather
    Crandall, John
    Kasamon, Yvette L.
    Ambinder, Richard F.
    Piantadosi, Steven
    Serena, Donna
    Kasecamp, Wayne
    Wahl, Richard L.
    MOLECULAR IMAGING AND BIOLOGY, 2017, 19 (03) : 429 - 436
  • [2] Initial experience with tositumomab and iodine I 131 tositumomab for treatment of relapsed/refractory Hodgkin lymphoma
    Jacene, Heather
    Kasamon, Yvette
    Ambinder, Richard
    Serena, Donna
    Kasecamp, Wayne
    Wahl, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [3] 131I-Tositumomab (Bexxar®) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience
    Iagaru, A.
    Knox, S.
    Goris, M. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S148 - S149
  • [4] A review of tositumomab and I131 tositumomab radioimmunotherapy for the treatment of follicular lymphoma
    Davies, AJ
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (04) : 577 - 588
  • [5] Phase I/II Dose-Escalation Study of Tositumomab and Iodine I 131 Tositumomab for Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin's Lymphoma: Feasibility and Initial Safety
    Jacene, Heather A.
    Kasamon, Yvette L.
    Ambinder, Richard F.
    Kasecamp, Wayne
    Serena, Donna
    Wahl, Richard L.
    BLOOD, 2008, 112 (11) : 1051 - 1052
  • [6] 131I-tositumomab therapy as initial treatment for follicular lymphoma
    Kaminski, MS
    Tuck, M
    Estes, J
    Kolstad, A
    Ross, CW
    Zasadny, K
    Regan, D
    Kison, P
    Fisher, S
    Kroll, S
    Wahl, RL
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (05): : 441 - 449
  • [7] The effectiveness of tositumomab and iodine I 131 tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL).
    Armitage, JO
    Leonard, JP
    Gregory, SA
    Horning, SJ
    Zelenetz, AD
    Kaminski, MS
    Fisher, RI
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 575S - 575S
  • [8] Characteristics of patients with relapsed and refractory low grade non-hodgkin's lymphoma who sustained durable responses following treatment with tositumomab and iodine I 131 tositumomab (Bexxar®).
    Gregory, SA
    Kaminski, MS
    Zelenetz, AD
    Jain, V
    BLOOD, 2002, 100 (11) : 312B - 312B
  • [9] Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab
    Quackenbush, Robert C.
    Horner, Thierry J.
    Williams, Vanessa C.
    Giampietro, Patricia
    Lin, Thomas S.
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 779 - 781
  • [10] 131I-Tositumomab in lymphoma
    Cheung, M. C.
    MacEachern, J. A.
    Haynes, A. E.
    Meyer, R. M.
    Imrie, K.
    CURRENT ONCOLOGY, 2009, 16 (05) : 32 - 47
12345